Clinical trials: Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumors
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
The purpose of this research is to test if mutations (changes in DNA) in exons (segment of DNA or RNA containing information that has the instructions for making proteins) in the KIT gene can be used to predict the body's…
- Trial name
- NCT05366816
- Testing
- Sunitinib, Regorafenib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Miami
Gastrointestinal Stromal Neoplasms
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine.
- Trial name
- NCT07585266
- Testing
- Velzatinib, Imatinib
- Where
- 93 sites in United States, Argentina and 18 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST)
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of imatinib (disease…
- Conditions
- Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
- Trial name
- ATEZOGIST (NCT05152472)
- Testing
- Atezolizumab 1200 mg, Imatinib 400 MG
- Where
- 13 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Leon Berard
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
GIST
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies.
- Trial name
- NCT05957367
- Testing
- Inlexisertib, Ripretinib
- Where
- 28 sites in United States, Denmark and 7 more
- Volunteers
- 94 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib.
- Trial name
- INTRIGUE (NCT03673501)
- Testing
- Ripretinib, Sunitinib
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 453 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastric Cancer, Gastric Neoplasm
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Objective: To follow people with GISTs and collect tumor tissue so that it can be studied in the lab. Eligibility: People age 6 and older who have a GIST.
- Conditions
- Gastric Cancer, Gastric Neoplasm, Gastrointestinal Stromal Sarcoma, Gastrointestinal Stromal Neoplasm
- Trial name
- NCT04557969
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor
Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors
This phase II trial tests the effect of autologous tumor infiltrating lymphocytes (TILs) in combination with interleukin-2 (aldesleukin) in treating patients with gastrointestinal stromal tumors (GIST) that has spread to nearby…
- Conditions
- Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor, Recurrent Gastrointestinal Stromal Tumor, Refractory Malignant Gastrointestinal Stromal Tumor
- Trial name
- NCT07647068
- Testing
- Aldesleukin, Biospecimen Collection, Chest Radiography
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Joal Beane
Gastrointestinal Stromal Tumors, Gastric Subepithelial Tumors
Development of a Multimodal AI System for GIST Management
Background: Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Accurate pre-operative diagnosis, risk stratification, and genotyping are critical for determining the…
- Conditions
- Gastrointestinal Stromal Tumors, Gastric Subepithelial Tumors, Gastric Leiomyoma, Artificial Intelligence (AI)
- Trial name
- NCT07454967
- Testing
- Multimodal AI Analysis System
- Where
- 9 sites in China
- Volunteers
- 300 people
- Sponsor
- Qun Zhao
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST)
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically…
- Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
- Trial name
- NCT05489237
- Testing
- IDRX-42
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 276 people
- Sponsor
- IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Gastrointestinal Neoplasms
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug…
- Trial name
- NCT07218926
- Testing
- IDRX-42, Sunitinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Gastrointestinal Neoplasms
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who…
- Trial name
- NCT07689201
- Testing
- Velzatinib
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Neoplasms
A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
This study aims to evaluate the long-term safety and tolerability of velzatinib (GSK6042981) in adults with GIST who have previously received velzatinib in parent study and continue to benefit from the treatment.
- Trial name
- NCT07843641
- Testing
- Velzatinib
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Adenocarcinoma (NOS), Anal Cancer
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease…
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- DP-04 (NCT07124000)
- Testing
- Trastuzumab deruxtecan
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Duodenal, Gastrointestinal Stromal Tumors
Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST
Gastrointestinal stromal tumour (GIST) is the most common mesenchymal neoplasm of the digestive tract, originating from the interstitial cells of Cajal.
- Trial name
- NCT07837271
- Where
- 2 sites in China
- Volunteers
- 288 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Cancer
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
- Trial name
- PALANGI3 (NCT01046487)
- Testing
- Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- Where
- 3 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Oscar Lambret
Gastrointestinal Neoplasms
Individual Patient Expanded Access for Velzatinib (GSK6042981) in Patients With Gastrointestinal Stromal Tumours With KIT Mutations
Compassionate Use, Individual Patient access to velzatinib (GSK6042981) for eligible patients with Gastrointestinal Stromal Tumours (GIST) who have KIT mutations and at least three prior lines of therapy
- Trial name
- NCT07825701
- Testing
- Velzatinib (GSK6042981)
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumors
Observational Registry Data on GIST Patients
This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
- Trial name
- NCT03602092
- Testing
- Observation
- Where
- Taiwan
- Volunteers
- 966 people
- Sponsor
- National Health Research Institutes, Taiwan
Gastrointestinal Stromal Tumor
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
This phase II trial is studying how well sorafenib works in treating patients with malignant gastrointestinal stromal tumor that progressed during or after previous treatment with imatinib mesylate and sunitinib malate.
- Trial name
- NCT00265798
- Testing
- Sorafenib Tosylate
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)